Skip to main content

Table 4 Instrinsic subset assignments in completers with at least two skin biopsies

From: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Patient

Response

Baseline subset

Post-treatment subset

N5

Improver

Inflammatory

Fibroproliferative

N10

Improver

Fibroproliferative

Normal-like

N11

Improver

Inflammatory

Normal-like

N16

Improver

Normal-like

Normal-like

N15

Non-improver

Fibroproliferative

Fibroproliferative

N19

Non-improver

Fibroproliferative

Fibroproliferative